Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 339

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Open access
Le, Xiuning, Nilsson, Monique, Goldman, Jonathan, Reck, Martin, Nakagawa, Kazuhiko, Kato, Terafumi, Ares, Luis Paz, Frimodt-Moller, Bente, Wolff, Katharina, Visseren-Grul, Carla, Heymach, John V., Garon, Edward B.·2021·Journal of Thoracic Oncology

Abstract

The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream signaling, and these pathways can function exclusively of one another during oncogenesis. In EGFR-mutant NSCLCs, up-regulated EGFR signaling increases VEGF through hypoxia-independent mechanisms, and elevated VEGF, in turn, contributes to the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs). In clinical trials, the addition of anti-VEGF therapy to EGFR TKIs considerably improved clinical outcomes. In recently reported large randomized studies, the addition of bevacizumab or ramucirumab to EGFR TKIs substantially improved progression-free survival in patients with TKI-naive EGFR-mutant NSCLC. This article reviews the preclinical and clinical data supporting dual inhibition of EGFR and VEGF in EGFR-mutant NSCLC as a way to improve patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.10.006

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 339

Metadata

Authors
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., Heymach, J. V., & Garon, E. B.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2021-02
Volume
16
Issue
2
Pages
205-215
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3094019790
Cited by
339
References
66
FWCI
17.85
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. https://app.cochat.ai/papers/10.1016/j.jtho.2020.10.006
The paper
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., Heymach, J. V., & Garon, E. B. (2021). Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.10.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.